Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Childhood Obesity
Interventions: Bottle Weaning Intervention; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Months to 13 Months
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Spasticity With Multiple Sclerosis
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more

Conditions: Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Interventions: Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy; Device · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Functional Seizures, Convulsion, Non-Epileptic
Interventions: ReACT, CATCH-IT; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 11 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab, Bevacizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 38 more

Conditions: Prostate Cancer
Interventions: Multiparametric MRI +/- prostate biopsy, Biparametric MRI +/- prostate biopsy; Diagnostic Test
Lead sponsor: University College, London; Other
Eligibility: 18 Years and older · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Rochester, Minnesota • New York, New York

Conditions: Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis, Virus Diseases, Digestive System Diseases, Hepatitis B, Chronic, Hepatitis B, DNA Virus Infections
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 1,640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Boston, Massachusetts + 2 more

Conditions: Venous Leg Ulcer (VLU)
Interventions: Topical Wound Oxygen Therapy, Sham Control Topical Wound Oxygen; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer
Interventions: palivizumab, ribavirin; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: zoledronic acid, quality-of-life assessment; Drug · Procedure
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 55
States / cities: Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more

Conditions: Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions: Gene Therapy product-MCO-010; Biological
Lead sponsor: Nanoscope Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 8
States / cities: Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 10
States / cities: Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more

Conditions: Hepatitis C, Chronic
Interventions: Interleukin 28B testing; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Chronic Hepatitis C Virus
Interventions: Velpatasvir, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 6 more

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis), MS, Multiple Sclerosis (MS) Secondary Progressive
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Kidney Disease
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more

Conditions: Chronic Hepatitis B
Interventions: TDF, Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 6 more

Conditions: Prader-Willi Syndrome, Hyperphagia
Interventions: Intranasal Oxytocin (IN-OXT), Matched Placebo; Drug
Lead sponsor: Eric Hollander; Other
Eligibility: 5 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cancer
Interventions: infection prophylaxis and management; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 12 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more

Conditions: Obesity, Food Habits
Interventions: General Nutrition Recommendations, Breakfast Recommendation, No Breakfast Recommendation; Behavioral
Lead sponsor: David Allison, Phd; Other
Eligibility: 20 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 1 more

Conditions: Acute Pain, Multiple Trauma, Fractures
Interventions: Ketamine, Hydromorphone; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pain
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more

Search by objective public record fields.

Feeding Young Children Study: Bottle Weaning Intervention

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS

A Multi-site Feasibility Clinical Trial of Retraining and Control Therapy (ReACT), a Mind and Body Treatment for Pediatric Functional Seizures

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

Prostate Imaging Using MRI +/- Contrast Enhancement

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

Trial to Evaluate Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic Venous Leg Ulcers

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Study of MLN8237 in Participants With Advanced Hematological Malignancies

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

A Study of LY3113593 in Participants With Chronic Kidney Disease

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Study of the Effectiveness of Breakfast Recommendations On Reducing Body Weight

Ketamine Patient-Controlled Analgesia for Acute Pain

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain